Polpril capsules 5mg №14х2

Name:
Half-pril caps. 5mg in bl. in pack. No. 14х2
Description:
Capsules with a light gray body and marking “5” and a green cap with marking “R”; the contents of the capsule are white or almost white powder. The main active ingredient oramipril Release form Capsules Dosage 5 mg Special instructions In patients with concomitant impaired renal function, doses are selected individually in accordance with QC values. Before starting treatment, all patients need to conduct a study of kidney function. In the course of treatment with ramipril, kidney function, electrolyte composition of the blood, the level of liver enzymes in the blood, as well as peripheral blood patterns (especially in patients with diffuse connective tissue diseases, in patients receiving immunosuppressants, allopurinol) are regularly monitored. Patients who have a fluid and / or sodium deficiency, before starting treatment, it is necessary to correct water and electrolyte disorders. During treatment with ramipril, hemodialysis using polyacrylonitrile membranes should not be performed (the risk of anaphylactic reactions is increased). Indications for use Arterial hypertension; chronic heart failure; heart failure that developed in the first few days after acute myocardial infarction; diabetic and non-diabetic nephropathy; reduction in the risk of myocardial infarction, stroke and cardiovascular mortality in patients with high cardiovascular risk, including patients with confirmed coronary artery disease (with or without a history of myocardial infarction), patients undergoing percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, with stroke in history and patients with occlusive lesions of peripheral arteries. Dosage and administration Take orally. The initial dose is 1.25-2.5 mg 1-2 times / day. If necessary, a gradual increase in dose is possible. The maintenance dose is set individually, depending on the indications for use and the effectiveness of treatment. Use during pregnancy and lactation Ramipril is contraindicated for use during pregnancy and lactation (breastfeeding). Interaction with other drugs With the simultaneous use of potassium-sparing diuretics (including spironolactone, triamterene, amiloride), potassium supplements, salt substitutes and dietary supplements containing potassium, hyperkalemia may develop (especially in patients with impaired renal function), because . ACE inhibitors reduce the content of aldosterone, which leads to a retention of potassium in the body against the background of limiting the excretion of potassium or its additional intake into the body. With simultaneous use with NSAIDs, it is possible to reduce the hypotensive effect of ramipril, impaired renal function. With simultaneous use with “loop” or thiazide diuretics, the antihypertensive effect is enhanced. Severe arterial hypotension, especially after taking the first dose of a diuretic, apparently occurs due to hypovolemia, which leads to a transient increase in the hypotensive effect of ramipril. There is a risk of developing hypokalemia. The risk of impaired renal function is increased. With simultaneous use with agents that have a hypotensive effect, it is possible to increase the hypotensive effect. With simultaneous use with insulin, hypoglycemic agents, sulfonylurea derivatives, metformin, hypoglycemia may develop. With simultaneous use with allopurinol, cystostatics, immunosuppressants, procainamide, the risk of developing leukopenia may increase. With simultaneous use with lithium carbonate, an increase in the concentration of lithium in the blood serum is possible. Contraindications Severe disorders of the kidneys and liver, bilateral stenosis of the renal arteries or stenosis of the artery of a single kidney; condition after kidney transplantation; primary hyperaldosteronism, hyperkalemia, aortic stenosis, pregnancy, lactation (breastfeeding), children and adolescents under 18 years of age, hypersensitivity to ramipril and other ACE inhibitors. Sostavramipril 5 mg Excipients: pregelatinized starch. The composition of the capsule shell: capsule body: gelatin, water, black iron oxide (E172), titanium dioxide (E171); capsule cap: gelatin, water, indigo carmine (E132), iron oxide yellow (E172), titanium dioxide (E171); ink Opacode S-1-277002 black: shellac, iron oxide black (E172), propylene glycol, ammonium hydroxide. Side effect From the side of the cardiovascular system: arterial hypotension; rarely – chest pain, tachycardia. From the side of the central nervous system: dizziness, weakness, headache; rarely – sleep disorders, mood. From the digestive system: diarrhea, constipation, loss of appetite; rarely – stomatitis, abdominal pain, pancreatitis, cholestatic jaundice. From the respiratory system: dry cough, bronchitis, sinusitis. From the urinary system: rarely – proteinuria, increased concentrations of creatinine and urea in the blood (mainly in patients with impaired renal function). From the hemopoietic system: rarely – neutropenia, agranulocytosis, thrombocytopenia, anemia. On the part of laboratory parameters: hypokalemia, hyponatremia. Allergic reactions: skin rash, angioedema and other hypersensitivity reactions. Other: rarely – muscle spasms, impotence, alopecia. Buy Polpril capsules 5mg No. 14×2 Price for Polpril capsules 5mg No. 14×2